4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT 2A receptor antagonists in Xenopus laevis oocytes

British Journal of Pharmacology

Volumn 141, Issue 7, 2004, Pages 1167-1174

  Villalobos, Claudio A ^a,e   Bull, Paulina ^b   Sáez, Patricio ^c   Cassels, Bruce K ^d   Huidobro Toro, J Pablo ^a  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT 2; Psychotropic phenylethylamines; Receptor antagonists; Subtype selective 5 HT 2

Indexed keywords

2,5 DIMETHOXYPHENETHYLAMINE; 4 BROMO 2,5 DIMETHOXYPHENETHYLAMINE; 4 IODO 2,5 DIMETHOXYPHENETHYLAMINE; 4 METHYL 2,5 DIMETHOXYPHENETHYLAMINE; 4 NITRO 2,5 DIMETHOXYPHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; INCUBATION TIME; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS LAEVIS;

ANIMALS; CLONING, MOLECULAR; DIMETHOXYPHENYLETHYLAMINE; DRUG ANTAGONISM; MICROINJECTIONS; OOCYTES; PHENETHYLAMINES; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 2342530990     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705722     Document Type: Article

References (29)

1. 2C receptors. Br. J. Pharmacol., 136, 510-519.
2. AGHAJANIAN, G.K. & MAREK, G.J. (1999). Serotonin and hallucinogens. Neuropsychopharmacology, 21, 16S-23S.
3. 2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefontal cortex. Eur. J. Neurosci., 11, 3064-3072.
4. BENLOUCIF, S., KEEGAN, M. & GALLOWAY, M. (1993). Serotonin- facilitated dopamine release in vivo: pharmacological characterization. J. Pharmacol. Exp. Ther., 265, 373-377.
5. 2 receptor activation potentiates N-methyl-D-aspartate receptor-mediated ion currents by a protein kinase C-dependent mechanism. J. Neurosci. Res., 45, 153-160.
6. de BOER, D., GIJZELS, M.J., Bosman, I.J. & Maes, R.A. (1999). More data about the new psychoactive drug 2C-B. J. Anal. Toxicol., 23, 227-228.
7. 2C receptor antagonist. Neuropharmacology, 36, 621-629.
8. 2C receptors. Br. J. Pharmacol., 115, 622-628.
9. 2A/2C receptor agonists. J. Med. Chem., 44, 1003-1010.
10. 2C receptors in the stimulus effects of hallucinogenic drugs: I. Antagonist correlation analysis. Psychopharmacology, 12, 347-356.
11. GEWIRTZ, J.C. & MAREK, G.J. (2000). Behavioral evidence for interaction between a hallucinogenic drug and group II meta-botropic glutamate receptors. Neuropsychopharmacology., 23, 569-576.
12. GIROUD, C., AUGSBURGER, M., RIVIER, L., MANGIN, P., SADEGHIPOUR, F., VARESIO, E., VEUTHEY, J.L. & KAMALAPRIJA, P. (1998). 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J. Anal. Toxicol., 12, 345-354.
13. 2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 35, 734-740.
14. 1C serotonin receptor binding. J. Med. Chem., 35, 4903-4910.
15. 2C receptor antagonist. Neuropharmacology, 36, 609-620.
16. 2C receptors. Neuropsychopharmacology, 18, 339-351.
17. 2a receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J. Pharmacol. Exp. Ther., 304, 229-237.
18. KURSAR, J.D., NELSON, D.L., WAINSCOTT, D.B. & BAEZ, M. (1994). Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol. Pharmacol., 46, 227-234.
19. McKENNA, D.J. & PEROUTKA, S.J. (1989). Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo- phenylisopropylamine and 3H-ketanserin. J. Neurosci., 9, 3482-3490.
20. 1A receptors: binding profiles and intrinsic activity. Pharmacol. Biochem. Behav., 40, 1041-1051.
21. 2C receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 359, 1-6.
22. NICHOLS, D.E. (1997). Role of serotonergic neurons and 5-HT receptors in the action of hallucinogens. In: Handbook of Experimental Pharmacology, Vol. 129, ed. BAUMGARTEN , H.G. & G.M. Chapter 21 pp 563-585. Berlin, Heidelberg: Springer.
23. 2A/2C agonist. J. Med. Chem., 37, 4346-4351.
24. PIERCE, P.A. & PEROUTKA, S.J. (1989). Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl), 97, 118-122.
25. PIERCE, P.A. & PEROUTKA, S.J. (1990). Antagonist properties of D-LSD at 5-hydroxytryptamine2 receptors. Neuropsychopharmacology., 3, 503-508.
26. 2C receptors. Brain Res. Mol. Brain Res., 23, 163-178.
27. 2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol. Blochem Behav., 72, 29-37.
28. SHULGIN, A.T. & SHULGIN, A. (1991). PIHKAL - A Chemical Love Story. Berkeley, CA: Transform Press.
29. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther., 266, 684-691.